Her2 amplification, Rel-A, and Bach1 can influence APOBEC3A expression in breast cancer cells
PLOS Genetics · 2024
DOI: 10.1371/journal.pgen.1011293 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Genetics, 2024. Verfasst von Madeline Dennis und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Molecular Biosciences and Center for Reproductive Biology, Washington State University, Pullman, Washington, United States of America. Hauptthemen laut MEDLINE: Basic-Leucine Zipper Transcription Factors, Breast Neoplasms, Cytidine Deaminase, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
APOBEC-induced mutations occur in 50% of sequenced human tumors, with APOBEC3A (A3A) being a major contributor to mutagenesis in breast cancer cells. The mechanisms that cause A3A activation and mutagenesis in breast cancers are still unknown. Here, we describe factors that influence basal A3A mRNA transcript levels in breast cancer cells. We found that basal A3A mRNA correlates with A3A protein levels and predicts the amount of APOBEC signature mutations in a panel of breast cancer cell lines, indicating that increased basal transcription may be one mechanism leading to breast cancer mutagenesis. We also show that alteration of ERBB2 expression can drive A3A mRNA levels, suggesting the enrichment of the APOBEC mutation signature in Her2-enriched breast cancer could in part result from elevated A3A transcription. Hierarchical clustering of transcripts in primary breast cancers determined that A3A mRNA was co-expressed with other genes functioning in viral restriction and interferon responses. However, reduction of STAT signaling via inhibitors or shRNA in breast cancer cell lines had only minor impact on A3A abundance. Analysis of single cell RNA-seq from primary tumors indicated that A3A mRNA was highest in infiltrating immune cells within the tumor, indicating that correlations of A3A with STAT signaling in primary tumors may be result from higher immune infiltrates and are not reflective of STAT signaling controlling A3A expression in breast cancer cells. Analysis of ATAC-seq data in multiple breast cancer cell lines identified two transcription factor sites in the APOBEC3A promoter region that could promote A3A transcription. We determined that Rel-A, and Bach1, which have binding sites in these peaks, elevated basal A3A expression. Our findings highlight a complex and variable set of transcriptional activators for A3A in breast cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Molecular Biosciences and Center for Reproductive Biology, Washington State University, Pullman, Washington, United States of America.
- Department of Microbiology and Molecular Genetics, University of Vermont Cancer Center, University of Vermont, Burlington, Vermont, United States of America.
ORCID-Profile: Nicholas Bray, Steven A Roberts
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- National Cancer Institute
- National Institute of General Medical Sciences
Zitieren
APA
Dennis, M., Hurley, A., Bray, N., Cordero, C., Ilagan, J., Mertz, T. M., & Roberts, S. A. (2024). Her2 amplification, Rel-A, and Bach1 can influence APOBEC3A expression in breast cancer cells. PLOS Genetics. https://doi.org/10.1371/journal.pgen.1011293
Vancouver
Dennis M, Hurley A, Bray N, Cordero C, Ilagan J, Mertz TM, et al. Her2 amplification, Rel-A, and Bach1 can influence APOBEC3A expression in breast cancer cells. PLOS Genetics. 2024. doi:10.1371/journal.pgen.1011293
BibTeX
@article{Dennis2024,
author = {Dennis, Madeline and Hurley, Alyssa and Bray, Nicholas and Cordero, Cameron and Ilagan, Jose and Mertz, Tony M and Roberts, Steven A},
title = {Her2 amplification, Rel-A, and Bach1 can influence APOBEC3A expression in breast cancer cells},
journal = {PLOS Genetics},
year = {2024},
doi = {10.1371/journal.pgen.1011293}
}
EUVIMED